TITLE

Biotech BOOM

AUTHOR(S)
O'REILEY, TIM
PUB. DATE
August 2008
SOURCE
Las Vegas Business Press (10712186);8/4/2008, Vol. 25 Issue 31, pP6
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the growth of biotechnology companies in the U.S. Las Vegas supporters in Nevada plan to capitalize on the emerging Nevada Cancer Institute, the Lou Ruvo Brain Institute and research programs at the University of Nevada. Milken Institute managing economist Kevin Klowden said that the city might have more success on drug manufacturing than research and development due to talent shortage. It says that the selling point of no state taxes in Nevada has little effect on the biotechnology industry.
ACCESSION #
34162045

 

Related Articles

  • The Changing Core Laboratory. Markin, Jeff // Applied Clinical Trials;Jan2009 Supplement, p10 

    The article focuses on the impact of Metrics Champion Consortium (MCC), continuous improvement programs, on biotechnology and pharmaceutical industry and service providers, particularly imaging core laboratories. It highlights qualities of laboratories that meet the need of sponsors to...

  • North American Pharma--Bio Capital Investment to Total $14.7-Billion for 2006. McCormick, Douglas // Pharmaceutical Technology;Apr2006, Vol. 30 Issue 4, p26 

    The article reports on capital investment of pharmaceutical and biotechnology companies and life science research institutions in North America for 2006. A study from Industrial Info Resources showed that there are more than 320 projects expected to begin construction in 2006. The study also...

  • Externalizing research through adaptive frameworks. Vedel, Jane Bjørn; Irwin, Alan; Andersen, Peter Høngaard // Nature Reviews Drug Discovery;Oct2013, Vol. 12 Issue 10, p723 

    The authors discuss aspects of the external research collaborations between academic research institutions and industry. They state that collaborations with academic research institutions are important part of the research and development (R&D) strategies of biotechnology and pharmaceutical...

  • Switzerland launches systems-biology initiative.  // Nature;12/13/2007, Vol. 450 Issue 7172, p932 

    The article reports on the launch of the System X, one of the world's largest systems-biology research consortiums, in Switzerland. The project is funded at around 200 million Swiss francs by the federal government, where half of which would support technology platforms at an ETH Zurich...

  • 2. MEDICAL RESEARCH CAPABILITIES IN BIOTECHNOLOGY IN AUSTRALIA: 2.2. LATENT DEMAND: ASPECTS OF INTEREST.  // Medical Research Capabilities in Biotechnology in Australia: A S;2003, p5 

    The article offers information about the research capabilities of the biotechnology sector in Australia. The research infrastructure in the country is composed of universities, the Commonwealth Scientific & Industrial Research Organisation, hospitals, research institutes, and other research and...

  • Increased Demand for Pediatric Trials Leads to BIO Initiative. Serebrov, Mari // BioWorld Today;5/9/2013, Vol. 24 Issue 89, p1 

    The article reports that the Biotechnology Industry Organization (BIO) is collaborating with ViS Research Institute on a two-phase effort to find qualified sites that can recruit pediatric subjects. This effort is in response to drug makers' growing interest in pediatric studies. The effort is...

  • Step out, play the game. Singh, Nandita // BioSpectrum;Mar2012, Vol. 10 Issue 3, p98 

    The author reflects on the importance for the pharmaceutical and biotechnology industries to ensure commitment to various research activities in India. She cites the availability of various funding from the government and private entities to leverage biotechnology research. However, the author...

  • CRO Industry Update. Brooks, Kristin // Contract Pharma;May2011, Vol. 13 Issue 4, p52 

    The article presents an analysis of the trends and developments in the pharmaceutical and biopharmaceutical industries. It mentions that globalization continues to play an important role in drug development efficiencies and clinical research organizations still maintain their efforts in...

  • Who Loves You?  // Pharmaceutical Executive;Jun2005, Vol. 25 Issue 6, p34 

    The article presents a study, which suggests the relationship between pharmaceutical and biotechnology companies and the clinical research centers with which they collaborate improved between 2003 and 2005. The study found that 75 percent of clinical research centers over-all rated relationships...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics